000078202 001__ 78202
000078202 005__ 20200716101528.0
000078202 0247_ $$2doi$$a10.14309/ctg.0000000000000003
000078202 0248_ $$2sideral$$a110714
000078202 037__ $$aART-2019-110714
000078202 041__ $$aeng
000078202 100__ $$aHerreros-Villanueva, M.
000078202 245__ $$aPlasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer
000078202 260__ $$c2019
000078202 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078202 5203_ $$aOBJECTIVES: Specific microRNA (miRNA) signatures in biological fluids can facilitate earlier detection of the tumors being then minimally invasive diagnostic biomarkers. Circulating miRNAs have also emerged as promising diagnostic biomarkers for colorectal cancer (CRC) screening. In this study, we investigated the performance of a specific signature of miRNA in plasma samples to design a robust predictive model that can distinguish healthy individuals from those with CRC or advanced adenomas (AA) diseases.
METHODS: Case control study of 297 patients from 8 Spanish centers including 100 healthy individuals, 101 diagnosed with AA, and 96 CRC cases. Quantitative real-time reverse transcription was used to quantify a signature of miRNA (miRNA19a, miRNA19b, miRNA15b, miRNA29a, miRNA335, and miRNA18a) in plasma samples. Binary classifiers (Support Vector Machine [SVM] linear, SVM radial, and SVM polynomial) were built for the best predictive model.
RESULTS: Area under receiving operating characteristic curve of 0.92 (95% confidence interval 0.871-0.962) was obtained retrieving a model with a sensitivity of 0.85 and specificity of 0.90, positive predictive value of 0.94, and negative predictive value of 0.76 when advanced neoplasms (CRC and AA) were compared with healthy individuals.
CONCLUSIONS: We identified and validated a signature of 6 miRNAs (miRNA19a, miRNA19b, miRNA15b, miRNA29a, miRNA335, and miRNA18a) as predictors that can differentiate significantly patients with CRC and AA from those who are healthy. However, large-scale validation studies in asymptomatic screening participants should be conducted.
000078202 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000078202 590__ $$a3.968$$b2019
000078202 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b32 / 88 = 0.364$$c2019$$dQ2$$eT2
000078202 592__ $$a1.811$$b2019
000078202 593__ $$aGastroenterology$$c2019$$dQ1
000078202 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000078202 700__ $$aDuran-Sanchon, S.
000078202 700__ $$aMartín, A.C.
000078202 700__ $$aPérez-Palacios, R.
000078202 700__ $$aVila-Navarro, E.
000078202 700__ $$aMarcuello, M.
000078202 700__ $$aDiaz-Centeno, M.
000078202 700__ $$aCubiella, J.
000078202 700__ $$aDiez, M.S.
000078202 700__ $$aBujanda, L.
000078202 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza
000078202 700__ $$aJover, R.
000078202 700__ $$aHernández, V.
000078202 700__ $$aQuintero, E.
000078202 700__ $$aJosé Lozano, J.
000078202 700__ $$aGarcía-Cougil, M.
000078202 700__ $$aMartínez-Arranz, I.
000078202 700__ $$aCastells, A.
000078202 700__ $$aGironella, M.
000078202 700__ $$aArroyo, R.
000078202 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000078202 773__ $$g10, 1 (2019), e00003 [9 pp]$$pCli. transl. gastroenterol.$$tClinical and Translational Gastroenterology$$x2155-384X
000078202 8564_ $$s184213$$uhttps://zaguan.unizar.es/record/78202/files/texto_completo.pdf$$yVersión publicada
000078202 8564_ $$s115788$$uhttps://zaguan.unizar.es/record/78202/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000078202 909CO $$ooai:zaguan.unizar.es:78202$$particulos$$pdriver
000078202 951__ $$a2020-07-16-09:32:21
000078202 980__ $$aARTICLE